NCT04974398 2025-04-13A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal CarcinomaAkesoPhase 3 Active not recruiting296 enrolled 1 FDA
NCT05563480 2022-12-01TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal CarcinomaChia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 2 Unknown90 enrolled